title: Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
authors.affiliation: University of Texas M.D. Anderson Cancer Center, Houston.
authors.forename: M J
authors.initials: MJ
authors.lastname: Keating
authors.forename: E
authors.initials: E
authors.lastname: Estey
authors.forename: H
authors.initials: H
authors.lastname: Kantarjian
authors.forename: W
authors.initials: W
authors.lastname: Plunkett
authors.forename: S
authors.initials: S
authors.lastname: O'Brien
authors.forename: C
authors.initials: C
authors.lastname: Koller
authors.forename: M
authors.initials: M
authors.lastname: Beran
authors.forename: E J
authors.initials: EJ
authors.lastname: Freireich
mesh_terms: D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000677:Amsacrine; D003561:Cytarabine; D014740:Vidarabine; C024352:fludarabine; D015255:Idarubicin; D003630:Daunorubicin